To the Editor: In the randomized trial of adjuvant chemotherapy for patients with stage IB or stage II non–small-cell lung cancer reported by Winton et al. (June 23 issue),¹ a statistically significant survival advantage was found overall, but no ...

To the Editor: In his Clinical Practice article (June 16 issue),¹ Abrams suggests that a 24-hour interval is warranted between the use of the phosphodiesterase inhibitors sildenafil, vardenafil, and tadalafil and the use of nitrates to prevent serious ...

To the Editor: In his Perspective article, Topol (July 14 issue)¹ discusses current clinical practice with respect to nesiritide. According to the Food, Drug, and Cosmetic Act, drug approval can be withdrawn when “new evidence of clinical experience, not ...

To the Editor: Avorn's proposal in his Perspective article (June 23 issue)¹ that the combination of torcetrapib and atorvastatin is market-driven, undermining its usefulness, is baseless. The program does not extend the patent on atorvastatin. Its basic ...

To the Editor: The case described by Medoff et al. (June 9 issue)¹ and a similar one published in the Journal eight years ago² illustrate how rapidly the acute respiratory distress syndrome (ARDS) related to sickle cell anemia can become irreversible. In ...

To the Editor: Post-marketing surveillance has revealed a higher incidence of reactivation of granulomatous infections — most notably, tuberculosis¹ and histoplasmosis² — in patients receiving the tumor necrosis factor α (TNF-α) inhibitor infliximab (...

To the Editor: Recently, a patient presented to our emergency department with severe poisoning after ingesting an aconite-containing tea with therapeutic intent. Her course highlights the potentially great danger of ingesting such a preparation. The ...